A pilot study, led by Dr Paul Chazot, Durham University, UK, and Dr Gordon Dougal, of Maculume Ltd, found improvements in the memory, motor function and processing skills of healthy people with normal intellectual function for their age.

As a result, the researchers said transcranial photobiomodulation therapy (PBM-T) – where infrared light is self-delivered to the brain using a specially designed helmet worn by the patient – might potentially also have benefits for people with dementia.

The PBM-T helmet has been devised by Dr Dougal, who is also a practising General Practitioner based in County Durham.

It works by delivering infrared light from 14 fan cooled LED light arrays deep into the brain, focused by the skull, at a wavelength of between 1,060 to 1,080 nanometres delivering 1,368J of energy to the cranium during each six-minute treatment cycle.

This stimulates the mitochondria that generate most of the chemical energy needed to power cells’ biochemical reactions. This in turn leads to a rise in the level of an organic compound called adenosine triphosphate (ATP), markedly decreased in dementia patients, that provides the energy to drive processes in living cells and help nerve cells to repair.

They stressed that more research into the use and effectiveness of the therapy was needed, but that the findings of their pilot were promising. The research is published in the journal Photobiomodulation, Photomedicine and Laser Surgery.

The research saw 14 healthy people, aged 45 and over, from the UK, receive six minutes of PBM-T twice daily at a wavelength of 1068 nanometres over a period of four weeks. This was carried out alongside a control group of 13 members using a dummy PBM-T helmet.

Scientists conducted a series of memory, verbal, and motor skills tests on the participants in both groups before and after the treatment period to see what improvements in function might have been achieved.

The researchers found a significant improvement in performance in motor function (finger tapping), memory performance (mathematical processing, a type of working memory), delayed memory and brain processing speed, in healthy people who had received PBM-T compared to those in the control placebo group.

Participants reported no adverse effects caused by the treatment.

Recommended

• US and UK AI research labs collaborate on army support tech
• Comment | Digital connectivity will empower people to restore our planet
• Report: Edinburgh top city outside London for high-growth businesses

Research Co-Lead Dr Paul Chazot, in the Department of Biosciences, Durham University, said: “We’ve shown what appears to be real improvements in memory and other neurological processes for healthy people when their brains are exposed to a specific wavelength of infrared light for consistent, short periods of time.

“While this is a pilot study and more research is needed, there are promising indications that therapy involving infrared light might also be beneficial for people living with dementia and this is worth exploring.

“Indeed, we and our US research collaborators recently also published a new independent clinical study which provides the first evidence for profound and rapid improvement in memory performance in dementia.

“We know that infrared light of particular wavelengths can help alleviate nerve cell damage, amyloid load and reduced blood flow in the brain, which are common in people with dementia, so could it be used as a game-changing multi-modal form of therapy?

“This could provide a novel disease-modifying strategy for dementia, with the potential to alleviate many of the serious problems faced by people with dementia and reduce the burden on their caregivers.”

The helmet can be easily worn by patients, meaning the therapy can be readily delivered at home. Researchers believe it might also be beneficial to other disorders, such as Parkinson’s, traumatic brain injury or motor neurone disease. Each helmet costs approximately £7,250 to buy.

Dr Gordon Dougal, research co-lead, of Maculume Ltd, said: “Current clinical practice can only set the stage for optimal recovery with little or no effect upon cellular function.

“Laboratory work exploring the mechanism of action of PBM-T1068, indicates this therapeutic tool may well help dying brain cells regenerate into functioning units once again.”

Get the latest news from DIGIT direct to your inbox

Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.

We will keep you up to date on the pivotal issues impacting the sector and let you know about key upcoming events to ensure that you don’t miss out on what’s going on across the Scottish tech community.

Click here to subscribe.